首页> 外文期刊>Vascular pharmacology >Nur77 downregulation triggers pulmonary artery smooth muscle cell proliferation and migration in mice with hypoxic pulmonary hypertension via the Axin2-beta-catenin signaling pathway
【24h】

Nur77 downregulation triggers pulmonary artery smooth muscle cell proliferation and migration in mice with hypoxic pulmonary hypertension via the Axin2-beta-catenin signaling pathway

机译:Nur77下调通过Axin2-β-catenin信号通路触发低氧性肺动脉高压小鼠的肺动脉平滑肌细胞增殖和迁移

获取原文
获取原文并翻译 | 示例
           

摘要

Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by remodeling of the pulmonary vasculature, including marked proliferation and reduced apoptosis of pulmonary artery smooth muscle cells (PASMCs). Members of the nuclear receptor 4A (NR4A) subfamily are involved in a variety of biological events, such as cell apoptosis, proliferation, inflammation, and metabolism. Activation of Nur77 (an orphan nuclear receptor that belongs to NR4A subfamily) has recently been reported to be as a beneficial agent in the treatment of cardiovascular and metabolic diseases. In the present study, we investigated the effects of NR4A on human PASMCs function in vitro and determined the underlying mechanisms. We found a robust expression of NR4A receptors in lung tissues of PAH patients and hypoxic mice but a highly significant downregulation within pulmonary arteries (PAs) as assessed by quantitative polymerase chain reaction, immunoblotting, and immunohistochemistry. In vitro, NR4A receptors were found significantly decreased in PASMCs derived from PAH patients. To explore the pathological effects of decreased Nur77 in PASMCs, PASMCs were transduced with siRNA against Nur77. The siRNA-mediated knockdown of Nur77 significantly augmented PASMCs proliferation and migration. In contrast, Nur77 overexpression prevented PASMCs from proliferation and migration. Mechanistically, overexpression of Axis inhibition protein 2 (Axin2) or inhibition of beta-catenin signaling was shown to be responsible for Nur77 knockdown-induced proliferation of PASMCs. Following hypoxia-induced angiogenesis of the pulmonary artery in C57BL/6 mice, small-molecule Nur77 agonists-Octaketide Cytosporone B (Csn-B) can significantly decreased thickness of vascular wall and markedly attenuated the development of chronic hypoxia-induced PAH in vivo. Therefore, reconstitution of Nur77 levels represents a promising therapeutic option to prevent vascular remodeling processes. (C) 2016 Elsevier Inc. All rights reserved.
机译:肺动脉高压(PAH)是一种威胁生命的疾病,其特征在于肺血管系统的重塑,包括肺动脉平滑肌细胞(PASMC)的明显增生和凋亡减少。核受体4A(NR4A)亚家族的成员参与多种生物学事件,例如细胞凋亡,增殖,炎症和新陈代谢。 Nur77(一种属于NR4A亚科的孤儿核受体)的激活最近被报道为治疗心血管和代谢疾病的有益药物。在本研究中,我们调查了NR4A对人PASMCs体外功能的影响,并确定了其潜在机制。我们通过定量聚合酶链反应,免疫印迹和免疫组织化学评估,发现PAH患者和低氧小鼠肺组织中NR4A受体表达稳定,但肺动脉(PAs)高度下调。在体外,在源自PAH患者的PASMC中发现NR4A受体显着降低。为了探讨减少的Nur77在PASMC中的病理作用,用siRNA转导了针对Nur77的PASMC。 siRNA介导的Nur77的敲低显着增强了PASMCs的增殖和迁移。相反,Nur77的过度表达阻止PASMC增殖和迁移。从机制上讲,轴抑制蛋白2(Axin2)的过表达或β-catenin信号的抑制被证明是Nur77敲低诱导的PASMCs增殖的原因。在C57BL / 6小鼠低氧诱导的肺动脉血管生成之后,小分子Nur77激动剂-奥曲肽Cytosporone B(Csn-B)可以显着降低血管壁厚度,并显着减弱体内慢性低氧诱导的PAH的发育。因此,重建Nur77水平代表了防止血管重塑过程的有前途的治疗选择。 (C)2016 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号